COVID-19 immunity in healthcare professionals

Determining whether there is protection against reinfection is important for controlling healthcare workers implications during the pandemic due to their continous professional contact with COVID-19 patients

Description of the Study:

  • Title: Immunitat en professionals sanitaris: cohort COVID CATCentral.
  • Principal Investigators: Carlota Dobaño, Anna Ramírez-Morros, Selena Alonso, Josep Vidal-Alaball, Gemma Ruiz-Olalla, Marta Vidal, Rocío Rubio, Emma Cascant, Daniel Parras, Natalia Rodrigo Melero, Pau Serra, Carlo Carolis, Pere Santamaria, Anna Forcada, Jacobo Mendioroz, Ruth Aguilar, Gemma Moncunill and Anna Ruiz-Comellas.
  • Centers of Implementation: Institut Català de la Salut, Institut de Salut Global de Barcelona (ISGlobal) and IDIAP Jordi Gol (IDIAP JG).
  • Study Population: Healthcare workers of Gerencia de la Catalunya Central (Bages, Berguedà, Anoia, Solsonès, Moianès and Osona) with clinic suggestive of COVID-19.
    – Inclusion criteria: Patients with clinical COVID-19 and at least one positive PCR or rapid antigen test will be included.
    – Exclusion criteria: Patients who do not agree to participate in the study.
  • Study Type: Prospective longitudinal cohort study.
  • Design: Prospective one-year longitudinal follow-up study of the COVID CATCentral cohort.
  • Methods: A total of 122 symptomatic primary health care professionals with positive PCR results for SARS-CoV-2 during the period of March 10 to April 10 will be studied. Clinical characteristics will be related to serological and cellular immunity results, collected in sequential monthly and bimonthly samples, respectively. Sequential plasma samples collected from 4 months to 16 months after symptom onset will be used.

Objectives of the Study:

Principal Objective: To characterize the SARS-CoV-2 antigen specific antibody profile and cellular immunity in blood samples collected prospectively for 12 months, by analyzing the kinetics, magnitude and durability in relation to the clinical presentation during the infection.

Secondary Objective: To describe the immunological factors associated with the different clinical manifestations of infection.

More about this Study:

Scientific Context: The immune response to SARS-CoV-2 virus with generation of antibodies (Ac) is observed, in most infected individuals, 10-15 days after the onset of COVID-19 symptoms. However, due to the recent emergence of this virus in the human population it is not yet known how long these Ac will be maintained or whether they will provide protection against reinfection.

Considering the possibility of a prolongation of the pandemic, the fact of having knowledge of immunity would translate into economic savings in diagnostic tests and in avoiding unnecessary isolations with the resulting socioeconomic impacts. It would also provide information at the pharmaceutical level in the treatment of serious patients and in the development of vaccines.

Fundacio Daniel Bravo1

Other Studies about Serology:

Effectiveness of vaccine combination

Científicos franceses demuestran que la vacunación primaria con dos vacunas diferentes sería más eficaz que la vacunación con dos vacunas idénticas.

COnV-ert study, convalescent plasma to stop COVID-19

Early administration of convalescent plasma in people over 50 years of age with mild to moderate COVID-19 disease may slow disease progression and decrease the severity of symptoms.

Mass SARS-CoV-2 Serological Screening in Andorra

This study aims to estimate the prevalence of antibodies against SARS-CoV-2 and help improve the prediction of infectious diseases and increase biosecurity in the Principality of Andorra.


SAPRIS-SERO is a study to estimate the seroprevalence of SARS-CoV-2 infection in the epidemiological cohorts Constances, E3-E4N, NutriNet-Santé and Elfe-Epipage2 in France.


Identifying true markers of protective immunity will allow for the identification of individuals, in particular healthcare personnel working with COVID-19 patients and in other critical areas protected from re-infection.


The COVICAT study aims to evaluate the evolution of the incidence of SARS-CoV-2 coronavirus infection in the Catalan population over a 12-month period.

Convalescent plasma therapy and COVID-19

Convalescent plasma with anti-SARS-CoV-2 antibodies appears to be a very promising approach in the context of protracted COVID-19 symptoms in patients unable to mount a specific humoral response to SARS-CoV-2.


COVonco Study

Join the COVonco study and help understand the impact of COVID-19 in oncology.

Fbdaf53c E60c 4f8c 9af5 Ce08e8ca65f0 4 5005 C


The EpiCOV project aims to provide a global and scientifically reliable mapping of the immune status of the population in France through serological tests and questionnaires.

REACT-2.5: Seroprevalence of SARS-CoV-2 antibodies

This cross-sectional study estimates SARS-CoV-2 IgG antibody seroprevalence in the community in England using self-administered LFIAs.